Board Member
Amneal Pharmaceuticals, Inc. (AMRX)Equibles does not estimate personal net worth.
Get an email with a short summary when Amneal Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AMRX alertsChirag Patel is recorded as Board Member and CEO at Amneal Pharmaceuticals, Inc. (AMRX). The newest filing on record that lists Chirag Patel as Board Member and CEO at Amneal Pharmaceuticals, Inc. (AMRX) is dated March 25, 2026. The proxy statement of Amneal Pharmaceuticals, Inc. reports total compensation of $8,691,745 for Chirag Patel in fiscal 2025, including a base salary of $800,000. Disclosed compensation is on record for 7 fiscal years. Chirag Patel has spoken on 26 earnings calls and 2 other investor events across 1 company, most recently for Amneal Pharmaceuticals, Inc. on July 30, 2026. Amneal Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Amneal Pharmaceuticals, Inc. includes Chintu Patel (CEO and Board Member), Paul Meister (Chairman and Board Member), Anastasios (Tasos) G. Konidaris (CFO) and 7 others.
“Emneal is in the midst of the most transformative period in our company's history.”
“It's been a nice Goldman dinner yesterday. Good investment bankers. It was fun.”
“Today is a defining moment for M.Neal. This morning, we announced that Amnil agrees to acquire Kashyyyk Biosciences, creating a fully integrated global biosimilars leader, and positioning Amnil to become the number one affordable medicines company in the United States.”
“So the journey for 2025 actually started in 2019. We call it MNIL 2.0, when my brother and I, we successfully ran a private company from founding of MNIL in 2002 to 2018.”
“2025 was a defining year of excellence excellent execution and portfolio expansion at emmio as a diversified biopharmaceutical company across specialty complex products injectables and biosimilars we're building category leadership positions in large and growing markets in 2025 Revenue grew 8%, adjusted EBITDA…”
Start not stated–present
Last confirmed March 25, 2026
Start not stated–present
Last confirmed March 25, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer and President | $800,000 | $8,691,745 |
| 2024 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer and President | $788,462 | $7,187,970 |
| 2023 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer and President | $750,000 | $2,370,386 |
| 2022 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer and President | $750,000 | $5,048,110 |
| 2021 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer and President | $724,038 | $4,785,116 |
| 2020 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer and President | $1 | $2,320,716 |
| 2019 | Amneal Pharmaceuticals, Inc. (AMRX) | Co-Chief Executive Officer and President | $44,226 | $337,967 |
